NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 109 filers reported holding NURIX THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,299,100 | -49.4% | 130,040 | -55.0% | 0.00% | -50.0% |
| Q1 2023 | $2,564,899 | +82161.0% | 288,840 | +1.5% | 0.01% | -38.5% |
| Q4 2022 | $3,118 | -99.9% | 284,701 | +19.5% | 0.01% | 0.0% |
| Q3 2022 | $3,101,000 | -61.8% | 238,204 | -61.1% | 0.01% | -7.1% |
| Q2 2022 | $8,124,000 | +90.5% | 612,002 | +100.4% | 0.01% | +7.7% |
| Q1 2022 | $4,265,000 | -17.2% | 305,340 | +72.8% | 0.01% | 0.0% |
| Q4 2021 | $5,152,000 | +72.0% | 176,666 | +83.4% | 0.01% | +85.7% |
| Q3 2021 | $2,995,000 | +281.0% | 96,350 | +228.4% | 0.01% | +250.0% |
| Q2 2021 | $786,000 | -80.4% | 29,340 | -77.3% | 0.00% | -77.8% |
| Q1 2021 | $4,008,000 | – | 129,240 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |